The use of dendritic cells (DCs) loaded with apoptotic tumor cells is an attractive approach to tumor vaccination in the absence of well-characterized tumor antigens. Apoptotic tumor cells are a convenient source of polyvalent tumor antigen, but may induce only weak immunization. We tested the role of replication-incompetent recombinant herpes simplex virus (HSV) d106 lacking all immediate early genes except ICP0 in the generation of apoptotic cells for tumor vaccination, using ID8-VEGF, a syngeneic mouse model of ovarian carcinoma expressing high levels of VEGF, and TC-1, a human papillomavirus (HPV) 16 E6-and E7-transformed adenocarcinoma. HSVd106 killed tumor cells by apoptosis. Tumor cells infected by HSVd106 were engulfed more avidly by immature DCs, and induced DC maturation more efficiently than tumor cells killed by ultraviolet B (UVB) radiation. HSVd106 infection induced stronger upregulation of heat shock protein (Hsp) 70 and glucose-related protein (GRP) 94 than UVB in cells undergoing apoptosis. Immunization of mice with DCs loaded with HSVd106-killed cells elicited stronger antitumor T-cell response, including tumor-reactive interferon-gamma-secreting and cytotoxic T cells, and resulted in significantly stronger delay in tumor growth than immunization with DCs loaded with UVB-killed tumor cells. Moreover, in the TC-1 model, a protective effect of vaccination (40% tumor free animals) was observed only after immunization with DCs loaded with HSVd106-killed cells. Thus, the use of replication-incompetent HSV strains lacking immediate early genes except ICP0 offers possible advantages in the preparation of whole tumor cell antigen for DC-based tumor vaccination.
Introduction
Dendritic cells (DCs) are important professional antigenpresenting cells that can induce antigen-specific primary immune responses against tumors. 1, 2 Vaccination therapy based on DCs loaded with tumor antigen has yielded promising results in tumors where specific tumor rejection antigens have been well characterized. 3 In tumors where such antigens have not been identified, vaccination with DCs loaded with whole apoptotic tumor cells has been proposed as an alternative. [4] [5] [6] Functional maturation of DCs is critical for efficient crosspresentation of antigen. 7 DCs derived from tumorbearing hosts have functional defects not present in DCs from healthy hosts, which may partly account for tumor immune evasion. 8 Although antigen uptake may induce maturation in DCs, apoptotic cells may provide less potent maturation-inducing signals than necrotic cells. 9 Expression of heat shock proteins (Hsp) and other danger signals during cell death was shown to enhance antigen presentation and induce antitumor immunity. 10, 11 Viral cell lysates have been used to prepare tumor vaccines. 12 Viral infection can induce apoptosis in host epithelial cells. For example, we and others have previously shown that replication-competent herpes simplex virus (HSV) strains kill tumor cells by apoptosis. [13] [14] [15] Viruses also trigger the release of inflammatory cytokines and chemokines, which may promote recruitment and activation of antigen-presenting cells. Viruses also induce potent 'danger' signals in infected host cells, such as Hsp, which have been shown to deliver tumor antigen to DCs. 16 HSV infection of epithelial cells leads to rapid upregulation of Hsp70, macrophage inflammatory protein (MIP)-1b, interleukin (IL)-1a, IL-1b and IL- 6, 17 suggesting that HSV infection may activate antigenpresenting mechanisms. However, wild-type viruses can also suppress the function of antigen-presenting cells. For example, replication-competent HSV strains have been shown to inhibit the maturation and antigen-presenting functions of DCs. [18] [19] [20] The HSV-1 genome comprises approximately 80 genes, which are expressed with temporal hierarchy following viral entry into the cell, and exert diverse and temporally related functions. Immediate-early (IE) or a genes ICP0, ICP4, ICP22, ICP27 and ICP47 are expressed within 4 h post-infection and have important regulatory functions. The loss of these genes renders HSV-1 unable to replicate, but enables it to kill the host cell. [21] [22] [23] We hypothesized that the use of replication-incompetent HSV-1 lacking all IE/a genes except ICP0 could be convenient tools for the preparation of whole tumor vaccines because they might trigger apoptosis in tumor cells while upregulating danger signals, thereby producing strongly immunogenic whole tumor antigen for the preparation of DC tumor vaccines. To test this hypothesis, we used HSVd106, a replication-incompetent HSV-1 mutant lacking ICP4, ICP22, ICP27 and ICP47, but expressing the ICP0 IE/a gene. 21, 24 We have previously demonstrated that human ovarian and cervical cancers are susceptible to infection and killing by recombinant attenuated HSV-1. 13, [25] [26] [27] Here, we used a syngeneic murine model of ovarian carcinoma generated in our laboratory 28 and the TC-1 model of human papillomavirus (HPV)-induced cancer. 29, 30 We demonstrate that HSVd106 efficiently kills tumor cells by apoptosis, while upregulating the expression of danger signals such as Hsp70 and glucose-related protein (GRP) 94. Tumor cells killed by HSVd106 were readily engulfed by immature DCs and enhanced DC maturation, improving tumor antigen presentation and the therapeutic efficacy of DC vaccines in vivo.
Materials and methods

Virus
The replication-incompetent HSV-1 mutant d106 (generously provided by Dr Neal DeLuca, Pittsburg University) lacks immediate early genes ICP4, ICP22, ICP27 and ICP47, and carries the green fluorescent protein (GFP) reporter gene under the control of the human cytomegalovirus promoter. Virus stocks were prepared and titrated in E11 cells and stored at À701C. The virus was purified as described elsewhere. 31 Briefly, supernatants of HSVd106-infected E11 cells were centrifuged at low speed to remove cell debris. The virus was concentrated, layered over 5-45% sucrose gradient and centrifuged for 1 h at 12 500 r.p.m. (Sorvall, AH627 rotor). Infectious virus used for the experiments was recovered from a fluffy white band at the center of the gradient. E11 cells were used to grow and titrate HSVd106. They were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin, in a 5% CO 2 atmosphere at 371C. Cells ID8, a cell line derived from spontaneous in vitro malignant transformation of C57BL/6 mouse ovarian surface epithelial cells, was a generous gift from Dr Paul F Terranova, 32 Kansas University. ID8 cell line was retrovirally modified to permanently overexpress the murine VEGF 164 isoform (ID8-VEGF), as described elsewhere.
Animals
27
ID8-VEGF cells were grown in a 5% CO 2 atmosphere at 371C in DMEM supplemented with 5% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin (all of them Invitrogen, Carlsbad, CA), 5 mg/ml insulin, 5 mg/ml transferrin and 5 ng/ml sodium selenite (Roche, Indianapolis, IN). The E11 cell line (generously provided by Dr Neal DeLuca, University of Pittsburgh) has been derived from green African monkey kidney Vero cells that were stably transfected with transcomplementing HSV-1 IE genes ICP4, ICP22, ICP27 and ICP47. 24 TC-1, a C57BL/6 mouse lung adenocarcinoma cell line transformed with HPV-16 E6 and E7, was a generous gift from Dr Yvonne Patterson, University of Pennsylvania. 33 TC-1 cells were maintained in RPMI (Invitrogen) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 10% FBS and geneticin (1 mg/ml) (Invitrogen) in a 5% CO 2 atmosphere at 371C.
Murine DCs were generated from CD34 þ bone marrow precursor cells as described previously. 28 Cells were differentiated with recombinant murine granulocytemacrophage colony-stimulating factor (GM-CSF; Peprotech, Rocky Hill, NJ; 20 ng/ml). 34 Cells were counted using Trypan blue. Differentiation into immature DCs was documented through flow cytometry detection of CD80, CD86 and major histocompatibility complex class II (MHC-II). DC maturation was induced by culturing cells in RPMI media under standard conditions in the presence of 10 ng/ml murine GM-CSF supplemented with 1 mg/ml lipopolysaccharide (LPS; Sigma Chemical Co., Saint Louis, MO) and 10 ng/ml tumor necrosis factoralpha (TNF-a, Sigma). Loading of DCs ID8-VEGF or TC-1 cells were infected with HSVd106 or exposed to UVB as above to induce apoptosis, rinsed three times with PBS, subjected to gamma irradiation (100 Gy from a 137 Cs source) and coincubated with immature murine DCs at a ratio of 1:1 (tumor cells, DCs) for 24 h. TNF-a (10 mg/ml) and LPS (1 mg/ml) were added for 2 additional days. DCs were then harvested, rinsed, and live cells were counted by the Trypan blue exclusion method. In some experiments, following induction of apoptosis, tumor cells were labeled with PKH26 fluorescent dye (Sigma; 5 mM) for 5 min at room temperature. RPMI supplemented with 10% FBS was added to stop the reaction and cells were rinsed three times prior to using them for pulsing DCs.
Tumor cell apoptosis
Flow cytometry
Cells were subjected to four-color flow cytometry on a FACSCalibur flow cytometer using CellQuest 3.2. 1f1 software (Becton Dickinson, San Jose, CA). We collected 10 4 events per sample. Nonspecific staining was blocked with anti-CD16/CD32 antibody (Fc block, 2.4G2; BD Pharmingen, San Diego, CA). Fluorochrome-conjugated monoclonal antibodies against CD11c (HL3), CD80 (16-10A1), CD86 (GL1), MHC-II (KH74; all BD Pharmingen, San Diego, CA), Hsp70 (453220; BD Transduction Lab, San Diego, CA), as well as rabbit polyclonal antibody against GRP94 (gp96; Santa Cruz Biotechnology, Santa Cruz, CA), were used according to the manufacturer's instructions. For intracellular cytokine staining, Brefeldin A (Sigma; 5 mg/ml) was added to cells 12 h before harvesting. Cells were first stained for cell surface antigens as above, washed, fixed, permeabilized with PBS, 0.2% bovine serum albumin (BSA, Sigma), 0.5% saponin for 5 min, and stained with monoclonal antibody against murine interferon-gamma (IFN-g; XMG1.2, BD Pharmingen). Samples were then washed with saponin-containing buffer and analyzed by flow cytometry.
Allogeneic lymphocyte proliferation
Murine C57BL/6 DCs were loaded with ID8-VEGF or TC-1 cells killed with UVB or HSVd106, incubated with TNF-a and LPS for 48 h, harvested with EDTA, washed twice with PBS and subjected to gamma irradiation (30 Gy). DCs were then seeded in 96-well round-bottom plates at various dilutions in RPMI containing 10% FBS. Spleens were resected from healthy BALB/c mice and minced in a sterile fashion to yield a single-cell suspension. Erythrocytes were eliminated by hypotonic shock. Splenocytes were plated in culture dishes in RPMI media under standard conditions for 120 min and the nonadherent fraction was subjected to Percoll gradient centrifugation to recover a highly pure population of lymphocytes. A constant number of BALB/c lymphocytes (1 Â 10 5 cells/well) were incubated with irradiated C57BL/ 6 DCs at increasing ratios (DC:lymphocytes) for 5 days at 371C. [ 3 H]thymidine (NEN Life Science, Boston, MA; 1 mCi/well) was added for 18 h at 371C. Samples were recovered on glass fiber filters using a Skatron cell harvester, and incorporation of radioactivity was measured by liquid scintillation counting using a Microbeta Trilux (Perkin Elmer Wallac, Inc., Gaithersburg, MD). Each determination was performed in triplicate.
Chemotaxis assay
Migration of murine DCs towards MIP-3a or MIP-3b (R&D Systems, Minneapolis, MN) was assessed in 96-well chemotaxis chambers using an 8-mm-pore nitrocellulose membrane (Neuroprobe, Gathersburg, MD). 35 Pyrogen-free RPMI 1640 containing 1% BSA was used as chemotactic media. Results are presented as chemotactic index (CI), defined as fold increase in cell migration in the presence of chemotactic factors compared to chemotactic media alone. Each determination was performed in triplicate.
Animal vaccination
DCs prepared from bone marrow precursors as above were loaded with ID8-VEGF or TC-1 cells killed by UVB or HSVd106 infection and incubated with TNF-a (10 mg/ ml) and LPS (1 mg/ml) for 2 additional days. Control DCs were not loaded with tumor, but matured with TNF-a and LPS. The routes of injection were picked, taking into account previous results in our lab. Thus, animals received two intraperitoneal (i.p.) doses of 1 Â 10 6 pulsed or control unpulsed DCs 15 days apart, followed by an additional subcutaneous (s.c.) dose of 1 Â 10 6 DCs.
Generation of antigen-specific T cells
Healthy mice (n ¼ 10 for each experimental group) were vaccinated with DCs loaded with ID8-VEGF cells killed by UVB or HSVd106 infection, or control-unloaded DCs. At 8 weeks following immunization, mice were euthanized and spleens were resected and minced in a sterile fashion to yield a single-cell suspension. Erythrocytes were eliminated by hypotonic shock. Splenocytes were plated in culture dishes in RPMI media under standard conditions for 120 min, and the nonadherent fraction was collected for further studies. Tumor-specific T cells were expanded by coculturing nonadherent splenocytes with autologous DCs loaded with ID8-VEGF cells killed by UVB at a ratio of 10:1 (T cells, DCs) in RPMI 1640 standard medium supplemented with IL-2 (R&D Systems; 20 IU/ml). Splenocytes were restimulated under the same conditions on day 7.
Autologous lymphocyte proliferation DCs loaded with ID8-VEGF cells killed with UVB or HSVd106 and incubated with TNF-a and LPS for 48 h were harvested with EDTA, washed twice with PBS and subjected to gamma irradiation (30 Gy For ELISPOT, 10 7 autologous nonadherent murine splenocytes were cultured with tumor-loaded or controlunloaded irradiated DCs at a ratio of 10:1 (T cells: DCs) in RPMI medium supplemented with 10% FBS. MultiScreen-IP plates (Millipore) were coated overnight at 41C with monoclonal antibody against mouse IFN-g (551216, BD Pharmingen; 50 ng/well) in sodium carbonate buffer (2.93 mg/ml sodium bicarbonate; 1.59 mg/ml sodium carbonate; 0.2 mg/ml sodium azide in distilled water). Plates were blocked with RPMI 10% FBS. T cells were suspended in RPMI 10% FBS (4 Â 10 5 T cells/ml) with irradiated DCs at a ratio of 10:1 (T cell: DCs) and plated in triplicate at 100 ml/well. After 20 h of incubation in standard culture conditions, cells were rinsed with PBST (PBS with 0.1% Tween-20). Biotinylated monoclonal antibody against mouse IFN-g (554410; BD Pharmingen; 2 mg/ml) was added to each well for 2 h in PBS containing 0.5% mouse serum and 0.1% Tween-20. The reaction was developed with streptavidin-HRP (BD Pharmingen) and aminoethyl-carbamide (AEC; Sigma) reagent. Spots were scanned and counted by computer-assisted ELISPOT image analysis (Hitech Instruments, Edgemont, PA). Digitalized images were analyzed for the presence of areas in which color density, spot size and circularity exceeded the background by a factor set on the basis of the comparison of control wells.
IFN-g ELISPOT
Cytotoxic T lymphocyte (CTL) assays
We performed standard lactate dehydrogenase-release assays to evaluate the development of tumor-specific CTLs as described in detail elsewhere. 36 We used T cells obtained from splenocytes of vaccinated and tumorbearing animals, through a Percoll gradient, as effector cells and ID8-VEGF or TC-1 cells as targets. The effector cells were not stimulated in vitro with target cells prior to the CTL assay. In order to characterize the effector cells, same experiments were performed after immunomagnetic depletion of CD4 þ , CD8 þ or NK cells. For this purpose, cells were incubated for 30 min with biotinylated antibodies against mouse CD8a (Ly3.4), CD4 (L3T4) or NK1.1 (PK136) (all from BD Pharmingen). Cells were rinsed with cold PBS with 1% BSA and incubated with streptavidin microbeads (BDt IMAG, BD Pharmingen). Positive cells were removed with a magnet (IMagnet, BD Pharmingen). Each determination was performed by triplicate.
ELISA
We used the matched anti-mouse detection and capture pairs: IL-4 (18031A) and biotinylated IL-4 (554390), IFN-g (551216) and biotinylated IFN-g (554410) (all BD Pharmingen). ELISA was performed using Immunoplatet Maxi Sorpt (Nalge Nunc International, Rochester, NY). ELISA plates were coated with tumor cell lysates (30 mg in carbonate buffer) and incubated for 2 h at 371C. Plates were blocked with 8% denatured milk in the same buffer for 2 h at 371C, washed five times with PBST and incubated with increasing dilutions of serum from treated and control animals. Plates were incubated at 41C overnight and washed five times with PBST. Biotinylated anti-mouse immunoglobulin G (Vector, Burlingame, CA) was added to each well (2 mg/well) for 2 h at 371C. The reaction was developed with streptavidin-HRP (BD Pharmingen, diluted 1:10 000 in PBS for 1 h at 371C) and the ABTS system (Roche Applied Science). Antibody titer was considered the reciprocal of the highest dilution at which serum antibody were detectable above the 0.15 OD cutoff point. Each sample was tested by duplicate.
Generation of tumors
Flank tumors were generated as previously described. 28 In brief, a single-cell suspension of ID8-VEGF cells was prepared in PBS mixed with an equal volume of cold Matrigelt (BD Biosciences) at 10 mg/ml. For flank injections, a total volume of 0.5 ml containing 7 Â 10 6 cells was injected s.c. into one flank of C57BL/6 mice (n ¼ 10). TC-1 tumors were generated by s.c. inoculation of 1 Â 10 4 TC-1 cells in 0.2 ml of PBS in C57BL/6 mice (n ¼ 10). Tumors were detectable 2 weeks later and were measured weekly using a Vernier caliper. Tumor volumes were calculated by the formula V ¼ 2 , where L is the length (longest dimension) and W is the width (shortest dimension).
Immunohistochemistry
Tumor cell cultures were immunostained using the VECTASTAIN ABC kit (Vector, Burlingame, CA), as recommended by the manufacturer. The primary antibodies used were: mouse monoclonal antibody against HSP70 (BD Transduction Lab) and rabbit polyclonal antibody against GRP94 (gp96, Santa Cruz Biotechnology). Anti-mouse and anti-rabbit VECTASTAIN ABC kits (Vector) were used as recommended by the manufacturer. Slides were counterstained with hematoxylin.
Statistical analysis
A one-way analysis of variance (ANOVA) followed by a Tukey-Kramer multiple comparison test was performed. A value of Po0.05 was considered significant. Data are expressed as mean7s.d.
Results
HSVd106 induces apoptosis in ID8-VEGF cells
We hypothesized that HSVd106 is able to infect cancer cells and induce rapid apoptosis owing to the loss of ICP4, ICP27 and ICP22, but the retention of ICP0. We assessed the effect of HSVd106 on ID8-VEGF and TC-1 cells in vitro. Nonconfluent cell monolayers were infected with HSVd106 at 0.1, 1 and 10 MOI. As shown in Figure 1a , the virus exerted a dose-dependent cytotoxic effect on ID8-VEGF cells, which was evident by MTS assay within 36 h of infection. Cell killing by the virus was confirmed by the detection of cytopathic effects (not shown). Typical features of apoptotic cell death were observed in ID8-VEGF cells after infection. Infected cells exhibited DNA laddering (Figure 1b) , annexin V staining ( Figure 1c) and DNA fragmentation detectable with the TUNEL assay (Figure 1d) . Identical results were obtained with TC-1 cells (not shown). Thus, HSVd106 induced a dose-dependent killing of tumor cells by apoptosis. Since we are going to use tumor cells killed by UVB as a control, we determined the amounts of UVB and HSVd106 that result in equivalent amount of killing of tumor cells. As shown in Figure 1c , exposure of ID8-VEGF or TC-1 cells to 1500 mW/cm 2 for 10 min or infection with HSVd106 at 10 MOI result in approximately 99% apoptosis rate by 36 h.
Killing of tumor cells by HSVd106 enhances antigen uptake and DC maturation
Apoptotic cells are engulfed by immature DCs, but may result in defective DC maturation and induction of tolerance rather than priming of adaptive immune responses. 37 We hypothesized that tumor cells killed by HSVd106 are engulfed more avidly by DCs and, although they die by apoptosis, they promote the maturation of DCs. We thus compared DCs engulfing tumor cells killed by HSVd106 to DCs engulfing tumor cells killed by UVB, which has been shown to induce mixed apoptosis and necrosis and to result in DCs capable of inducing antitumor immune response. 34 First, we tested whether DCs differentially engulf tumor cells killed by replication-incompetent HSV or UVB. To quantify the uptake of apoptotic bodies by DCs, ID8-VEGF cells were labeled with PKH26 fluorescent dye prior to pulsing of DCs. Cells were then stained with antibody against CD11c, and CD11c þ DCs were analyzed for PKH26 expression with flow cytometry. Immature DCs engulfed ID8-VEGF cells killed by HSVd106 more efficiently than ID8-VEGF cells killed by UVB, as assessed by flow cytometry evaluation of PKH26 in DCs. Less than half of DCs were PKH26 positive when incubated with ID8-VEGF cells killed by UVB, while approximately 75% of DCs were PKH26 positive when incubated with cells killed by HSVd106 (Figure 2a) .
Next, we examined the phenotype of DCs following engulfment of ID8-VEGF cells killed by HSVd106. To assess DC maturation, we tested their ability to induce nonspecific proliferation of allogeneic lymphocytes and to migrate towards MIP-3a versus MIP-3b. We also quantified the expression of MHC-II and costimulatory molecules CD86 and CD80. DCs were loaded in vitro with killed ID8-VEGF cells and then incubated with equal amounts of TNF-a and LPS for 48 h. DCs loaded with cells killed with HSVd106 induced stronger proliferation of allogeneic lymphocytes than DCs loaded with UVBkilled cells (Figure 2b) . A similar switch in chemotactic behavior was seen in DCs loaded with tumor cells killed by either agent; DCs lost the ability to migrate towards MIP-3a and acquired the ability to migrate towards MIP3b, indicating maturation (Figure 2c ). Control-unloaded DCs matured with TNF-a and LPS exhibited weaker migration towards MIP-3b, while immature DCs were chemoattracted only by MIP-3a. Finally, increased maturation was seen when DCs were loaded with virally killed tumor cells compared to UVB-killed tumor cells, as assessed by expression of MHC-II, CD86 and CD80 (Figure 2d ). These data collectively show that apoptosis induced by HSVd106 enhances DC antigen uptake and maturation.
HSVd106 induces expression of 'danger signals'
We hypothesized that infection by replication-incompetent HSV-1 upregulates 'danger signals' in dying tumor cells. We tested the expression of two molecules associated with acute stress response, Hsp70 and GRP94. A significant upregulation of Hsp70 and GRP94 was detected by flow cytometry in ID8-VEGF cells infected by HSVd106 (Figure 3a and c) . We further confirmed this observation using immunohistochemistry. Upregulation of Hsp70 and GRP94 was clearly detected within 24 h from infection by HSVd106 at 1 MOI (Figure 3b and d) . Cells exposed to an equivalent lethal dose of UVB showed weaker upregulation of Hsp70 and GRP94 (Figure 3a  and c) . Identical results were obtained with TC-1 cells (not shown). Thus, replication-incompetent HSV-1 induced tumor cell apoptosis, while strongly upregulating 'danger signals'.
DCs loaded with tumor cells killed by HSVd106 induce antitumor immune response
We hypothesized that DCs loaded with apoptotic tumor cells killed by HSVd106 induce efficient antitumor immune response in vivo. We thus evaluated cellular and humoral response to tumor antigen following vaccination with 1 Â 10 6 DCs loaded with tumor cells killed by either HSVd106 or UVB, or with control unloaded DCs. Animals were vaccinated three times, twice i.p. followed by once s.c. 2 weeks apart. Immune response was evaluated on splenocytes 3 weeks after the last dose.
Splenocytes isolated from animals vaccinated as above were incubated with autologous tumor antigen presented by DCs loaded with ID8-VEGF cells killed by UVB. Significant proliferation was detected in splenocytes isolated from animals vaccinated with DCs loaded with tumor cells killed by HSVd106 compared to unloaded DCs. When the same splenocytes were coincubated with DCs loaded with TC-1, proliferation was similar to the observed in the nonvaccinated group (data not shown), indicating the presence of tumor-specific T-cell precursors (Figure 4a) . A higher amount of proliferation was observed in splenocytes from animals vaccinated with DCs loaded with HSV-killed tumor cells compared to DCs loaded with UVB-killed tumor cells (Po0.05). By ELISPOT, we detected a significantly higher frequency of tumor-specific IFN-g secreting T cells among splenocytes from animals vaccinated with DCs loaded with HSVkilled tumor cells compared to DCs loaded with UVBkilled tumor cells (Figure 4b ). This result was confirmed by intracellular staining for IFN-g (Figure 4c ) and ELISA quantification of IFN-g in cell supernatants (Figure 4d vaccinated with DCs loaded with UVB-killed tumor cells (Figure 4f ). We detected circulating tumor-specific antibodies by sandwich ELISA in vaccinated animals, but no significant difference was observed between animals vaccinated with DCs loaded with HSV-killed tumor cells and animals vaccinated with DCs loaded with UVB-killed tumor cells (Figure 4g ). Similar results were obtained following vaccination with DCs pulsed with TC-1 cells. The increase in antitumor antibody levels in mice vaccinated with DCs loaded HSV-killed tumor cells, together with an increase in IFN gamma and no changes in the frequency of IL-4-producing cells, suggested that the higher titer could be related to IgG2a antibodies.
DCs loaded with tumor cells killed by HSVd106 delay tumor growth
We have previously shown that, although ID8-VEGF tumors express MHC-I, they are immunologically tolerated under routine transplantation conditions. 28 We hypothesized that vaccination with DCs loaded with tumor cells killed by HSVd106 could hinder the growth of ID8-VEGF tumors. Animals vaccinated as above were challenged 3 weeks after the last vaccine with 5 Â 10 6 live ID8-VEFG cells inoculated s.c. to the flanks. Control animals received mature unloaded DCs. All animals developed tumors, including controls and animals vaccinated with DCs pulsed with HSVd106-infected or UVBkilled ID8-VEGF cells. As shown in Figure 5a , vaccinated mice exhibited significantly delayed tumor growth. Importantly, a greater delay was noted in animals vaccinated with DCs loaded with HSV-killed tumor cells compared to animals vaccinated with DCs loaded with UVB-killed tumor cells.
Animals were killed 16 weeks after tumor inoculation and splenocytes were used in cytotoxic assays in order to evaluate the specific response against syngeneic tumor cells. As shown in Figure 5b , incubation of effector cells with neutralizing antibody anti-CD4 or anti-NK1.1 had no effect on their ability to kill target tumor cells. In contrast, incubation with neutralizing anti-CD8 antibody significantly reduced cytotoxicity to animals vaccinated with DCs loaded with HSV-killed tumor cells. Similar results were seen with splenocytes from animals vaccinated with DCs loaded with UVB-killed tumor cells (not shown).
A similar experiment was performed with the TC-1 model. A higher percentage of tumor-free animals was observed in animals vaccinated with DCs pulsed with HSVd106-infected cells compared to DCs pulsed with UVB-irradiated TC-1 cells (Figure 5c ). Moreover, comparing only tumor-bearing animals among groups, the growth of TC-1 tumors was significantly delayed in animals vaccinated with DCs pulsed with TC-1 cells killed by HSVd106 compared to animals vaccinated with DCs pulsed with TC-1 cells killed by UVB, or with control unpulsed DCs (Figure 5d ).
Discussion
As tumor-associated antigens are not well characterized for the majority of human tumors, polyvalent vaccines prepared with whole tumor antigen are an attractive approach to induce tumor vaccination. Apoptotic tumor cells have been considered a convenient source of whole tumor antigen to prepare DCs for tumor vaccination. 4, 5 However, engulfment of apoptotic bodies may induce only weak maturation of DC, resulting in weak immunization or even tolerance. 37, 38 Here, we show that replicationincompetent HSV-1 lacking all IE/a genes except ICP0 is a suitable approach to killing tumor cells in order to pulse DCs for tumor vaccination. Although tumor cells infected by the virus died through apoptosis, they induced strong DC maturation and resulted in tumor vaccination.
Tumor cells infected by HSVd106 exhibited high expression of stress response proteins Hsp70. Hsps have been shown to be induced by other viruses such as adenovirus, 39 vaccinia virus 40 and cytomegalovirus. 41 Previous work has shown that infection of epithelial cells by replication-competent, wild-type or attenuated HSV-1 leads to rapid upregulation of Hsp70, 17 which occurs within seven hours from infection. 42 The present data show that viral entry and/or expression of ICP0 alone are capable of inducing upregulation of Hsp70 in both host cells. Hsp70 provides potent danger signals which act as general adjuvants that promote the maturation of DCs and disruption of tolerance. 10, 11, 43 These molecular chaperones also act as vehicles harvesting peptides within dying cells and delivering them to professional antigenpresenting cells, thus playing a critical role in promoting antigen crosspresentation and eliciting tumor-specific protective immunity. 44, 45 These observations provide a possible molecular mechanism by which HSVd106-mediated apoptosis elicits efficient DC maturation and tumor antigen presentation.
Other immunostimulatory factors may be induced during HSV infection. Wild-type HSV-1 upregulates IL1a, IL-1b, IL-6 and MIP-1a very early during infection in epithelial cells. 17 These inflammatory cytokines may play a role in promoting DC maturation. Type-1 interferons also induce potent activation of antigen-presenting cells. 46, 47 The interferon response in infected host cells is, however, inhibited by ICP0, 48 suggesting that these mechanisms may play a marginal role in the context of infection by HSVd106.
UVB irradiation has been proposed as an efficient method to prepare whole tumor antigen, and has been shown to result in a mixed population of apoptotic and necrotic tumor cells. 24 We recently reported that DCs loaded with autologous tumor cells killed with UVB elicit efficient expansion of tumor-specific T-cell precursors ex vivo in patients with ovarian cancer. 49 Here we show that the use of the replication-incompetent HSVd106 is a superior method to kill tumor cells than UVB radiation for the purpose of preparing tumor antigen. It is interesting to note that UVB induced weaker upregulation of stress response proteins Hsp70, in keeping with the important regulatory role that these proteins play in antigen presentation.
The present data complements previous evidence that recombinant herpes is a convenient tool for tumor vaccination. 50 Intratumoral injections of attenuated HSV-1-G207 lacking ICP34.5 and ribonucleotide reductase were shown to elicit strong in situ tumor vaccination in syngeneic mouse models of colorectal carcinoma and malignant melanoma. 51 A specific T-cell response against the immunodominant MHC-I-restricted tumor epitope AH1 was detected in animals receiving intratumoral oncolytic HSV-1. 52 Tumor cells infected with attenuated HSV-1 have also been used as efficient vaccines. 53 However, both wild-type and attenuated HSV-1 have been shown to inhibit DC maturation. 52, 53 Thus, replication-incompetent HSV-1 such as HSVd106 may be more advantageous for tumor vaccination. A variety of common solid tumors have proven sensitive to HSV infection and killing, including ovarian and cervical cancer, as we have shown, 13, [25] [26] [27] 54 as well as breast, 55 prostate, 56 lung, 57 colorectal 58 and head and neck squamous carcinoma, 59 mesothelioma 60 and melanoma. 61 In addition, tumors of neuronal origin are readily infected by HSV-1. 62 Thus, the potential applications of replication-incompetent HSV-1 extend to a large number of malignancies. As, for the majority of these tumors, whole tumor antigen represents the only feasible approach to tumor vaccination presently, replication-incompetent HSV-1-1 may prove useful to improve the efficacy of DC-based vaccines.
In our ID8-VEGF model, although we observed a significant induction of antitumor immune response with the use of HSV-1-killed tumor cells, animals were not protected entirely from tumor growth. In this respect, our model reflects human ovarian carcinoma, where tumor immune surveillance ameliorates outcome but does not prevent tumor occurrence. 63 A stronger antitumor response was observed in the TC-1 model. This may be due to the expression of higher levels of MHC-I molecules by TC-1 cells compared to ID8-VEGF cells (our own unpublished observations), or due to the expression of high levels of VEGF by the ovarian model, which may suppress antitumor immune response. 8, 28 The s.c. models lend themselves to further investigation aiming at enhancing the efficacy of immunotherapy and circumventing tumor immune escape mechanisms. The use of replication-incompetent HSV-1 offers specific advantages in this regard because the large genome of HSV-1 can accommodate multiple transgenes. Delivery of cytokines, additional danger molecules, costimulatory molecules or tumor-associated antigens could enhance the function of DCs in vivo and boost immune responses to specific dominant peptides that can mediate tumor regression.
